ValuEngine upgraded shares of Horizon Pharma PLC (NASDAQ:HZNP) from a hold rating to a buy rating in a research note issued to investors on Monday, October 16th.
Several other research firms have also issued reports on HZNP. BidaskClub upgraded shares of Horizon Pharma PLC from a hold rating to a buy rating in a report on Saturday, June 24th. UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the company a buy rating in a report on Tuesday, August 8th. Piper Jaffray Companies set a $18.00 target price on shares of Horizon Pharma PLC and gave the company a buy rating in a report on Monday, August 7th. Cantor Fitzgerald set a $13.00 target price on shares of Horizon Pharma PLC and gave the company a buy rating in a report on Monday, July 31st. Finally, BMO Capital Markets reaffirmed a buy rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. Horizon Pharma PLC currently has an average rating of Buy and an average target price of $18.00.
Horizon Pharma PLC (HZNP) traded up 1.21% on Monday, reaching $13.78. The company’s stock had a trading volume of 1,752,004 shares. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $21.98. The stock’s 50 day moving average is $13.19 and its 200-day moving average is $12.66. The firm’s market capitalization is $2.25 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 earnings per share. Analysts predict that Horizon Pharma PLC will post $1.07 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Horizon Pharma PLC (NASDAQ:HZNP) Rating Increased to Buy at ValuEngine” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/horizon-pharma-plc-hznp-upgraded-at-valuengine.html.
A number of hedge funds have recently modified their holdings of HZNP. Bank of New York Mellon Corp grew its position in Horizon Pharma PLC by 3.1% in the 1st quarter. Bank of New York Mellon Corp now owns 764,571 shares of the biopharmaceutical company’s stock worth $11,300,000 after purchasing an additional 22,918 shares in the last quarter. Prudential Financial Inc. grew its position in Horizon Pharma PLC by 2.6% in the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 420 shares in the last quarter. American International Group Inc. grew its position in Horizon Pharma PLC by 5.3% in the 1st quarter. American International Group Inc. now owns 97,675 shares of the biopharmaceutical company’s stock worth $1,444,000 after purchasing an additional 4,888 shares in the last quarter. Wellington Management Group LLP bought a new stake in Horizon Pharma PLC in the 1st quarter worth about $730,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in Horizon Pharma PLC in the 1st quarter worth about $151,000. 82.68% of the stock is owned by institutional investors and hedge funds.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.